The Coordination Overhead That Slows CDx Programs
FDA CDx guidance requires thorough analytical validation documentation timed to align with the therapeutic's NDA/BLA. In practice, that means tracking validation study completion against a PMA-supplement timeline while managing a partner IVD vendor whose priorities don't always align with your drug program's critical path. Milestone conversations live across Translational Medicine Slack channels and IVD vendor meeting notes. Compiling an accurate picture of where the program actually stands — not where the last status deck said it stood — consumes disproportionate senior time.
Agents Across the CDx Regulatory Workflow
An AI Labor Company agent mines CDx development milestone workflows from translational-medicine Slack and IVD vendor meeting notes, then deploys agents to auto-compile analytical validation summaries structured per current FDA CDx guidance and track PMA-supplement timelines in the regulatory tracker. IVD partner communications are drafted for review before any external contact. The VP Translational Medicine approves all partner-facing communications — the agent handles the production and tracking work that would otherwise require a dedicated regulatory operations contractor on each program.
Cost Reduction and Program Protection
CDx regulatory consulting is billed at rates that reflect a small pool of practitioners with both FDA IVD experience and oncology biomarker expertise. An agent that handles validation summary compilation, milestone tracking, and partner communication drafting can reduce that spend by 35–55% per co-development program. The program is typically operational in about 20 weeks. Beyond the direct savings, the more important benefit is risk reduction: a CDx timeline that slips relative to the NDA/BLA can delay the entire drug program. Tighter operational coordination is program protection.
Does the agent understand FDA CDx guidance requirements specifically?
Yes. The analytical validation summary compilation is structured against current FDA guidance for companion diagnostics. The agent is configured for this regulatory context, not generic document management.
How is communication with the IVD partner handled?
The agent drafts all partner-facing communications for review before they're sent. Nothing goes to the IVD partner without explicit approval from the VP Translational Medicine or their designee.